m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT02071			[1]
m⁶A modification Dnmt3a Dnmt3a YTHDF2 : m⁶A sites Direct Inhibition DNA methylation DNMT3A DACH1
m6A Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
m6A Target	Cysteine methyltransferase DNMT3A (DNMT3A)			Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	DNA methylation (DNAMeth)
Epigenetic Regulator	Cysteine methyltransferase DNMT3A (DNMT3A)		WRITER	View Details
Regulated Target	Dachshund family transcription factor 1 (DACH1)			View Details
Crosstalk Relationship	m6A → DNA methylation		Inhibition
Crosstalk Mechanism	m6A modification directly impacts DNA methylation through modulating the expression level of DNA methyltransferases or demethylases.
Crosstalk Summary	This study suggests that YTHDF2 regulates Cysteine methyltransferase DNMT3A (DNMT3A) expression and nuclear translocation to modulate dendritic cell function and Th17/Treg balance through Dachshund family transcription factor 1 (DACH1)/c-Jun pathway in COPD.
Responsed Disease	Chronic obstructive pulmonary disease	ICD-11: CA22		Disease Info
Cell Process	Differentiation
Cell Process	balance
In-vivo Model	Male BALB/c mice (SJA Laboratory Animal Company, Hunan, China) with age of 6-8 weeks were used in this study to establish COPD model. Mice were housed in individually ventilated cages under a pathogen-free condition, with ad libitum access to food and water. Animal welfare was monitored daily, and all efforts were made to minimize suffering. All animal procedures were conducted in accordance with the guidelines for use of laboratory animals, with approval from the Institutional Animal Care and Use Committee at Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College).

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

Cysteine methyltransferase DNMT3A (DNMT3A)		8 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	PMID27376512-Compound-Figure3CN		Patented	[2]
MOA	Inhibitor
Activity	EC50 = 1100 nM
External Link	CID: 117968550 TTD: D02VTV
Compound Name	PMID27376512-Compound-Figure3CG		Patented	[2]
MOA	Inhibitor
Activity	EC50 = 2400 nM
External Link	CID: 117967861 TTD: D03LZO
Compound Name	PMID27376512-Compound-Figure3CM		Patented	[2]
MOA	Inhibitor
Activity	EC50 = 1100 nM
External Link	CID: 117976053 TTD: D0F8AB
Compound Name	PMID27376512-Compound-Figure2aExample1		Patented	[2]
MOA	Inhibitor
Activity	IC50 = 3000 nM
External Link	CID: 71521835 TTD: D01LUJ
Compound Name	PMID27376512-Compound-MTC-424		Patented	[2]
MOA	Inhibitor
Activity	IC50 = 1940 nM
External Link	TTD: D02WRM
Compound Name	PMID27376512-Compound-MTC-427		Patented	[2]
MOA	Inhibitor
Activity	IC50 = 295 nM
External Link	TTD: D0HA0J
Compound Name	PMID27376512-Compound-MTC-422		Patented	[2]
MOA	Inhibitor
Activity	IC50 = 1430 nM
External Link	TTD: D0QY0N
Compound Name	PMID27376512-Compound-MTC-423		Patented	[2]
MOA	Inhibitor
Activity	IC50 = 363 nM
External Link	TTD: D0W9VZ
CA22: Chronic obstructive pulmonary disease		207 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Carbocisteine		Approved	[3]
Synonyms	Carbocysteine; Siroxyl; Carbocisteine, Sopar Click to Show/Hide
External Link	CID: 193653 TTD: D0X5SI DrugBank: DB04339
Compound Name	Aclidinium		Approved	[4]
Synonyms	UNII-K17VY42F6C; K17VY42F6C; CHEBI:65346; 727649-81-2; CHEMBL551466; (3R)-3-[2-hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; SCHEMBL72141; GTPL7449; SCHEMBL15096073; CHEMBL1194325; DTXSID00223070; ZINC30691727; BDBM50296331; DB08897; AJ-84146; AB01565828_02; 1-(3-Phenoxypropyl)-3alpha-[hydroxybis(2-thienyl)acetyloxy]-1-azoniabicyclo[2.2.2]octane Click to Show/Hide
External Link	CID: 11434515 TTD: D0VP1V DrugBank: DB08897
Compound Name	Roflumilast		Approved	[5]
Synonyms	162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast Click to Show/Hide
External Link	CID: 449193 TTD: D0R4UW DrugBank: DB01656
Compound Name	Tiotropium		Approved	[6]
Synonyms	186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide Click to Show/Hide
External Link	CID: 5487427 TTD: D0P1WA DrugBank: DB01409
Compound Name	Fluorometholone		Approved	[3]
Synonyms	Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione Click to Show/Hide
External Link	CID: 9878 TTD: D0P0HT DrugBank: DB00324
Compound Name	Bamifylline		Approved	[3]
Synonyms	Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride Click to Show/Hide
External Link	CID: 16229 TTD: D0O7SP DrugBank: DB13203
Compound Name	Maraviroc		Phase 3	[7]
Synonyms	376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc Click to Show/Hide
External Link	CID: 3002977 TTD: D0NR6S DrugBank: DB04835
Compound Name	Glycopyrrolate		Approved	[8]
Synonyms	596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide Click to Show/Hide
External Link	CID: 11693 TTD: D0M0AM
Compound Name	Salmeterol		Approved	[9]
Synonyms	Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol Click to Show/Hide
External Link	CID: 5152 TTD: D0L5YV DrugBank: DB00938
Compound Name	Vilanterol		Approved	[10]
Synonyms	503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair Click to Show/Hide
External Link	CID: 10184665 TTD: D0L0GM DrugBank: DB09082
Compound Name	MK-08887A		Approved	[3]
Synonyms	DULERA Click to Show/Hide
External Link	CID: 71301227 TTD: D0K3WO
Compound Name	Revefenacin		Approved	[11]
Synonyms	UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7 Click to Show/Hide
External Link	CID: 11753673 TTD: D0K1ST DrugBank: DB11855
Compound Name	Prasterone		Approved	[12]
Synonyms	Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone Click to Show/Hide
External Link	CID: 5881 TTD: D0K0EK DrugBank: DB01708
Compound Name	Meprednisone		Approved	[3]
Synonyms	Betapar Click to Show/Hide
External Link	CID: 5284587 TTD: D0I5DS DrugBank: DB09383
Compound Name	Theophylline		Approved	[13]
Synonyms	Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione Click to Show/Hide
External Link	CID: 2153 TTD: D0F8RA DrugBank: DB00277
Compound Name	Almitrine		Approved	[14]
Synonyms	Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine Click to Show/Hide
External Link	CID: 33887 TTD: D0D9NA DrugBank: DB01430
Compound Name	Arformoterol		Approved	[15]
Synonyms	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate Click to Show/Hide
External Link	CID: 3083544 TTD: D0D1DI DrugBank: DB01274
Compound Name	Incruse Ellipta		Approved	[3]
Synonyms	Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2 Click to Show/Hide
External Link	CID: 11519069 TTD: D09ZOQ
Compound Name	LAS-34273		Approved	[16]
Synonyms	Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide Click to Show/Hide
External Link	CID: 11519741 TTD: D07KHH
Compound Name	Bitolterol		Approved	[3]
Synonyms	Tornalate Click to Show/Hide
External Link	CID: 35330 TTD: D06RUL DrugBank: DB00901
Compound Name	Olodaterol		Approved	[17]
Synonyms	BI-1744 Click to Show/Hide
External Link	CID: 11504295 TTD: D04UTT DrugBank: DB09080
Compound Name	Symbicort		Approved	[18]
Synonyms	(22R)-Budesonide; UNII-2HI1006KPH; 51333-22-3; 51372-29-3; 2HI1006KPH; DSSTox_CID_202; DSSTox_RID_75430; DSSTox_GSID_20202; (1~{s},2~{s},4~{r},6~{r},8~{s},9~{s},11~{s},12~{s},13~{r})-9,13-Dimethyl-11-Oxidanyl-8-(2-Oxidanylethanoyl)-6-Propyl-5,7-Dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-Dien-16-One; R-Budesonide; Budesonide-22R; NCGC00016862-01; EINECS 257-161-7; CAS-51333-22-3; BUDESONIDE (11beta,16alpha(R)); SCHEMBL4095; AC1L22VC; CHEMBL2110662 Click to Show/Hide
External Link	CID: 40000 TTD: D04QNO
Compound Name	Indacaterol		Approved	[19]
Synonyms	312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone Click to Show/Hide
External Link	CID: 6918554 TTD: D03DJL DrugBank: DB05039
Compound Name	Benralizumab		Approved	[20]
External Link	TTD: D02PIO
Compound Name	Anoro		Approved	[3]
Synonyms	Umeclidinium + vilanterol Click to Show/Hide
External Link	TTD: D02CKO
Compound Name	Pregabalin		Approved	[21]
Synonyms	Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer Click to Show/Hide
External Link	CID: 5486971 TTD: D00WUF DrugBank: DB00230
Compound Name	Relvar/Breo		Approved	[22]
Synonyms	Vilanterol + fluticasone furoate Click to Show/Hide
External Link	CID: 71306415 TTD: D00WMK
Compound Name	Umeclidinium		Approved	[23]
External Link	CID: 11519070 TTD: D00SLY DrugBank: DB09076
Compound Name	Aclidinium/formoterol		Phase 4	[24]
Synonyms	(S,S)-Formoterol; CHEBI:63081; (S,S)-N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formaldehyde; NCGC00025167-01; 67346-48-9; Tocris-1448; AC1MHY5S; ZINC856 Click to Show/Hide
External Link	CID: 3034756 TTD: D0Q1IT
Compound Name	Ozagrel		Phase 4	[25]
Synonyms	Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika Click to Show/Hide
External Link	CID: 5282440 TTD: D0C7AA DrugBank: DB12017
Compound Name	Levosalbutamol/ipratropium		Phase 4	[26]
Synonyms	8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-; 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane (3-endo,8-syn)- Click to Show/Hide
External Link	CID: 43232 TTD: D06PTA
Compound Name	Itepekimab		Phase 3	[27]
External Link	TTD: DPT90B
Compound Name	MEDI3506		Phase 3	[28]
Synonyms	Tozorakimab Click to Show/Hide
External Link	TTD: DOTF14
Compound Name	Astegolimab		Phase 3	[29]
Synonyms	MSTT1041A; RG6149 Click to Show/Hide
External Link	TTD: DBAL18
Compound Name	SAR440340		Phase 3	[27]
Synonyms	Itepekimab Click to Show/Hide
External Link	TTD: D8U1EX
Compound Name	Olodaterol/tiotropium bromide		Phase 3	[30]
Synonyms	136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0 Click to Show/Hide
External Link	CID: 5487426 TTD: D0Z7AB
Compound Name	PT005		Phase 3	[31]
Synonyms	Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005 Click to Show/Hide
External Link	CID: 6917983 TTD: D0YS2W
Compound Name	Tozorakimab		Phase 3	[28]
External Link	TTD: D0YFN1
Compound Name	GSK642444		Phase 3	[32]
Synonyms	threo isoleucyl thiazolidide, 1; BDBM17299 Click to Show/Hide
External Link	CID: 23647689 TTD: D0T6TW
Compound Name	Arofylline		Phase 3	[33]
Synonyms	Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione Click to Show/Hide
External Link	CID: 166553 TTD: D0T0NG
Compound Name	Lebrikizumab		Phase 3	[34]
Synonyms	RG3637 Click to Show/Hide
External Link	TTD: D0SM8S
Compound Name	PT003		Phase 3	[31]
External Link	TTD: D0S1KP
Compound Name	PT001 GP		Phase 3	[35]
External Link	TTD: D0Q7QA
Compound Name	QVA-149		Phase 3	[36]
Synonyms	Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol Click to Show/Hide
External Link	CID: 11564052 TTD: D0Q5AT
Compound Name	Darotropium + 642444		Phase 3	[37]
External Link	CID: 25195533 TTD: D0H0UB
Compound Name	QMF149		Phase 3	[38]
Synonyms	Indacaterol, mometasone furoate Click to Show/Hide
External Link	TTD: D0E0XL
Compound Name	SUN-101		Phase 3	[39]
External Link	TTD: D04RNN
Compound Name	Bococizumab		Phase 3	[40]
External Link	TTD: D03DJT
Compound Name	Mitiperstat		Phase 2	[41]
Synonyms	1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1933460-19-5; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; Azd 4831; AZD 4831 [WHO-DD]; AZD4831; AZD-4831; AZD-4831 [WHO-DD]; BDBM312172; BHKKSKOHRFHHIN-MRVPVSSYSA-N; CHEMBL5095218; compound 16 [PMID: 36005476]; CS-0376445; EX-A7129; GLXC-26157; GTPL12154; HY-145581; Mitiperstat; Mitiperstat [INN]; MITIPERSTAT [USAN]; S6GYK3X4QQ; SCHEMBL17782047; UNII-S6GYK3X4QQ; US9616063, 3 Click to Show/Hide
External Link	CID: 121362450 TTD: D87IQS
Compound Name	OrM3		Phase 2b	[32]
External Link	TTD: D06CVO
Compound Name	Bimosiamose		Phase 2a	[42]
Synonyms	TBC 1269; TBC-1269 Click to Show/Hide
External Link	CID: 9811353 TTD: D02AUB DrugBank: DB06197
Compound Name	CSJ117		Phase 2	[43]
Synonyms	Ecleralimab Click to Show/Hide
External Link	TTD: DU6O4B
Compound Name	AZD8871		Phase 2	[44]
Synonyms	1435519-06-4; 2-THIOPHENEACETIC ACID, .ALPHA.-HYDROXY-.ALPHA.-2-THIENYL-, TRANS-4-((3-(5-((((2R)-2-(1,2-DIHYDRO-8-HYDROXY-2-OXO-5-QUINOLINYL)-2-HYDROXYETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)METHYLAMINO)CYCLOHEXYL ESTER; 2-Thiopheneacetic acid, alpha-hydroxy-alpha-2-thienyl-, trans-4-((3-(5-((((2R)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl)amino)methyl)-1H-benzotriazol-1-yl)propyl)methylamino)cyclohexyl ester; AKOS040750679; Azd 8871; AZD 8871 [WHO-DD]; AZD8871; AZD-8871; BDBM50528210; CHEMBL4297483; CS-0079218; EX-A7799; HY-120802; LAS191351; LAS-191351; Navafenterol; NAVAFENTEROL [INN]; Navafenterol [USAN]; SCHEMBL16429536; SCHEMBL22766780; TRANS-4-((3-(5-((((2R)-2-HYDROXY-2-(8-HYDROXY-2-OXO-1,2-DIHYDRO-5- QUINOLINYL)ETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)(METHYL)AMINO)CYCLOHEXYL HYDROXY(DI-2-THIENYL)ACETATE; U29GY32XJ4; UNII-U29GY32XJ4; WHO 11100 Click to Show/Hide
External Link	CID: 71558565 TTD: DM63YS
Compound Name	YPL-001		Phase 2	[45]
External Link	TTD: DGT7B6
Compound Name	DS102		Phase 2	[46]
External Link	TTD: DGL7Z2
Compound Name	QBW251		Phase 2	[47]
Synonyms	(S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 1334546-77-8; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; AKOS040759841; AMB0BO0WFH; BDBM297402; CHEMBL4650318; compound 33 [PMID: 34028270]; CS-0116371; DTXSID601336884; GTPL11547; HY-109177; Icenticaftor; Icenticaftor [INN]; Icenticaftor [USAN:INN]; Icenticaftor [USAN]; MS-25717; Qbw251; QBW-251; SCHEMBL2372751; UNII-AMB0BO0WFH; US10117858, Example 5; WHO 11246 Click to Show/Hide
External Link	CID: 58442344 TTD: DFV1I4
Compound Name	SelK2		Phase 2	[48]
External Link	TTD: DFTV08
Compound Name	GSP 304		Phase 2	[49]
External Link	TTD: D6AZ5H
Compound Name	AZD7594		Phase 2	[50]
External Link	CID: 67041274 TTD: D0X9YP
Compound Name	TA-2005		Phase 2	[33]
Synonyms	Carmoterol hydrochloride; CHF 4226.01; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1) Click to Show/Hide
External Link	CID: 63951 TTD: D0VU2M
Compound Name	Interferon-alpha lozenge		Phase 2	[51]
Synonyms	Veldona (TN) Click to Show/Hide
External Link	TTD: D0U7SU
Compound Name	Tetomilast		Phase 2	[52]
Synonyms	145739-56-6; 6-(2-(3,4-Diethoxyphenyl)thiazol-4-yl)picolinic acid; OPC-6535; UNII-S6RXB5KF56; S6RXB5KF56; 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-6-pyridyl)thiazole; 2-Pyridinecarboxylicacid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-; 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid; Tetomilast [INN]; 6-(2-(3,4-Diethoxyphenyl)-1,3-thiazol-4-yl)pyridine-2-carboxylic acid; OPC 6535; ACMC-1BW9F; AC1MHG07; SCHEMBL436663; GTPL9877; CHEMBL332750; CTK0H7037; OPC6535; DTXSID00163149 Click to Show/Hide
External Link	CID: 3025803 TTD: D0T6IM DrugBank: DB05298
Compound Name	TPI-1020		Phase 2	[53]
Synonyms	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate Click to Show/Hide
External Link	TTD: D0T5TU
Compound Name	Vasoactive intestinal peptide		Phase 2	[54]
Synonyms	CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP Click to Show/Hide
External Link	CID: 53314964 TTD: D0T4TN
Compound Name	AZD1981		Phase 2	[55]
Synonyms	802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603 Click to Show/Hide
External Link	CID: 11292191 TTD: D0T4SG DrugBank: DB11946
Compound Name	SB-656933		Phase 2	[56]
Synonyms	Elubrixin; UNII-MW2AIJ8USP; MW2AIJ8USP; SB-656933-AAF; 688763-64-6; CHEMBL2178579; Elubrixin [USAN:INN]; SB656933; elubirixin; Elubrixin (USAN); SCHEMBL1562280; GTPL8499; DTXSID60218962; BDBM50398333; DB12135; SB 656933; D10332 Click to Show/Hide
External Link	CID: 10479502 TTD: D0SN7I DrugBank: DB12135
Compound Name	GSK1325756		Phase 2	[57]
Synonyms	Danirixin; 954126-98-8; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea Click to Show/Hide
External Link	CID: 24780598 TTD: D0R7XD DrugBank: DB11922
Compound Name	Igmesine		Phase 1	[33]
Synonyms	Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen Click to Show/Hide
External Link	CID: 6438340 TTD: D0N5LJ
Compound Name	PF-489791		Phase 2	[58]
Synonyms	UNII-2S27T3DSZ3; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide Click to Show/Hide
External Link	CID: 11465695 TTD: D0M9FQ DrugBank: DB11736
Compound Name	BCT-197		Phase 2	[59]
Synonyms	BCT-197-A2201 Click to Show/Hide
External Link	CID: 11338127 TTD: D0M6PA DrugBank: DB15448
Compound Name	ONO-6126		Phase 2	[33]
Synonyms	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709 Click to Show/Hide
External Link	CID: 9864321 TTD: D0M5BS
Compound Name	AZD-2115		Phase 2	[60]
Synonyms	Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca Click to Show/Hide
External Link	TTD: D0L9CD
Compound Name	EP-101		Phase 2	[61]
Synonyms	106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409 Click to Show/Hide
External Link	CID: 7832 TTD: D0KX9B
Compound Name	PH-797804		Phase 2	[62]
Synonyms	586379-66-0; PH797804; PH 797804; 3-(3-Bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide; UNII-SI09I1V827; UNII-GEL7GRJ3R6; GEL7GRJ3R6; CHEMBL1088751; CHEBI:82715; SI09I1V827; 3-{3-Bromo-4-[(2,4-Difluorobenzyl)oxy]-6-Methyl-2-Oxopyridin-1(2h)-Yl}-N,4-Dimethylbenzamide; PHA-797804; 1358027-80-1; 3-Bromo-4-((2,4-difluorobenzyl)oxy)-1-(5-((methylamino)carbonyl)-2-methylphenyl)-6-methylpyridin-2(1H)-one; 3hll; KCAJXIDMCNPGHZ-UHFFFAOYSA-N Click to Show/Hide
External Link	CID: 22049997 TTD: D0K2ZF DrugBank: DB07941
Compound Name	LAS 100977		Phase 2	[63]
Synonyms	LABA Click to Show/Hide
External Link	CID: 11962616 TTD: D0J1AV DrugBank: DB12100
Compound Name	PF-3635659		Phase 2	[64]
Synonyms	PF-03635659 Click to Show/Hide
External Link	CID: 16065403 TTD: D0I5XU DrugBank: DB12408
Compound Name	Lancovutide		Phase 2	[65]
Synonyms	Duramycin; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio Click to Show/Hide
External Link	CID: 86289378 TTD: D0H8XB
Compound Name	PS-938285		Phase 2	[66]
External Link	TTD: D0H8GW
Compound Name	GSK961081		Phase 2	[67]
Synonyms	CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate Click to Show/Hide
External Link	CID: 10372836 TTD: D0GP8P DrugBank: DB12526
Compound Name	Haemophilus recombinant vaccine		Phase 2	[68]
External Link	TTD: D0GM8E
Compound Name	Carmoterol		Phase 2	[69]
Synonyms	147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1 Click to Show/Hide
External Link	CID: 63952 TTD: D0G0RT
Compound Name	LIRIMILAST		Phase 2	[70]
Synonyms	Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester Click to Show/Hide
External Link	CID: 6433118 TTD: D0F5IY
Compound Name	AZD-2423		Phase 2	[71]
Synonyms	CCR2b antagonist (pain, COPD), AstraZeneca Click to Show/Hide
External Link	CID: 46213922 TTD: D0E5NY
Compound Name	UK-432097		Phase 2	[72]
Synonyms	Adenosine A2a agonist (asthma), Pfizer Click to Show/Hide
External Link	CID: 9833519 TTD: D0D5VJ DrugBank: DB12691
Compound Name	AZD9056		Phase 2	[73]
Synonyms	AZD-9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide Click to Show/Hide
External Link	CID: 10161381 TTD: D0CS2C DrugBank: DB12594
Compound Name	BIO-11006		Phase 2	[74]
External Link	TTD: D0C3XD
Compound Name	PF-03715455		Phase 2	[75]
Synonyms	UNII-0TJ631J0KP; 1056164-52-3; 0TJ631J0KP; CHEMBL1938400; PF-3715455; 2yis; SCHEMBL981777; GTPL8179; DTXSID70147214; BDBM50361467; SB16724; DB12138 Click to Show/Hide
External Link	CID: 11714580 TTD: D0A1WN DrugBank: DB12138
Compound Name	IC-485		Phase 2	[33]
External Link	CID: 23724885 TTD: D09USN
Compound Name	TOFIMILAST		Phase 2	[76]
Synonyms	CP-325366; Tofimilast < Prop INN; 9-Cyclopentyl-7-ethyl-3-(2-thienyl)-5,6-dihydro-9H-pyrazolo[3,4-c][1,2,4]triazolo[4,3-a]pyridine Click to Show/Hide
External Link	CID: 9896267 TTD: D09TFB DrugBank: DB11681
Compound Name	ODSH		Phase 2	[77]
Synonyms	Cardiac ischemia reperfusion injury therapy, ParinGenix; ODSH (iv); PGX-100; PGX-200; ODSH (inhaled formulation), ParinGenix; ODSH (iv), ParinGenix; 2-O, 3-O desulfated heparin (inhaled), ParinGenix; 2-O, 3-O heparin (intravenous formulation), ParinGenix Click to Show/Hide
External Link	TTD: D09AWM
Compound Name	AZD-8683		Phase 2	[78]
External Link	TTD: D08WSG
Compound Name	AER-002		Phase 2	[79]
Synonyms	Aerolytic; Bikunin; Pulmolytic; Bikunin, Aerovance; Bikunin, Bayer Click to Show/Hide
External Link	TTD: D07YRV
Compound Name	QBM076		Phase 2	[80]
External Link	TTD: D06SCQ
Compound Name	GSK233705		Phase 2	[32]
External Link	TTD: D05KXJ
Compound Name	AZD-9164		Phase 2	[81]
Synonyms	IDDBCP239717 Click to Show/Hide
External Link	CID: 44517831 TTD: D05GNW DrugBank: DB12115
Compound Name	QAX-028		Phase 2	[82]
Synonyms	Bronchodilatory agent (inhaled, COPD), Novartis Click to Show/Hide
External Link	TTD: D04XVE
Compound Name	AZD7624		Phase 2	[83]
External Link	CID: 25143624 TTD: D04SPJ
Compound Name	GSK2245840		Phase 2	[84]
Synonyms	Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione, Click to Show/Hide
External Link	CID: 25108829 TTD: D04JNI DrugBank: DB12186
Compound Name	THRX-198321		Phase 2	[85]
Synonyms	Beta 2 adrenoreceptor agonist/muscarinic receptor antagonist (asthma), Theravance Click to Show/Hide
External Link	TTD: D04GRB
Compound Name	TRN-157		Phase 2	[86]
Synonyms	LAMA antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals; Long acting muscarinic M3 antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals Click to Show/Hide
External Link	TTD: D02TXV
Compound Name	AZD9668		Phase 2	[87]
Synonyms	Alvelestat; 848141-11-7; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide Click to Show/Hide
External Link	CID: 46861623 TTD: D02PHE DrugBank: DB11863
Compound Name	SB-265610		Phase 2	[33]
Synonyms	SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, > J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be Click to Show/Hide
External Link	CID: 9841667 TTD: D02JXG
Compound Name	AQX-1125		Phase 2	[88]
Synonyms	AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox Click to Show/Hide
External Link	CID: 76965484 TTD: D02HDG DrugBank: DB13012
Compound Name	JNJ-10311795		Phase 2	[89]
Synonyms	CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid Click to Show/Hide
External Link	CID: 10146470 TTD: D01YIO
Compound Name	SCH-527123		Phase 2	[90]
Synonyms	Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659 Click to Show/Hide
External Link	CID: 9865554 TTD: D00QKI
Compound Name	O-desulfated heparin		Phase 2	[91]
Synonyms	Intravenous Click to Show/Hide
External Link	TTD: D00AKQ
Compound Name	Zofin		Phase 1/2	[92]
External Link	TTD: D9XJ0U
Compound Name	CCI 15106		Phase 1	[93]
External Link	TTD: DSM39E
Compound Name	PUR1800		Phase 1	[94]
External Link	TTD: DG2EK3
Compound Name	BI 1323495		Phase 1	[95]
External Link	TTD: D8PO7Y
Compound Name	GSK3923868		Phase 1	[96]
External Link	TTD: D5KX2H
Compound Name	CHF 5407		Phase 1	[32]
External Link	TTD: D0V0JQ
Compound Name	AZD-9819		Phase 1	[97]
Synonyms	Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca Click to Show/Hide
External Link	CID: 24890141 TTD: D0U0AU
Compound Name	RG-7103		Phase 1	[98]
Synonyms	R-7103; RO-5024118; VPAC2 agonist (COPD), Roche Click to Show/Hide
External Link	CID: 90871060 TTD: D0S7UQ
Compound Name	AZD4721		Phase 1	[99]
External Link	TTD: D0Q0RK
Compound Name	Ronomilast		Phase 1	[100]
Synonyms	ELB-353; PDE4 inhibitor, BioTie; PDE4 inhibitor, elbion; AWD-12-353 Click to Show/Hide
External Link	CID: 9803446 TTD: D0O8JW
Compound Name	AZD-5122		Phase 1	[101]
External Link	TTD: D0N3QF
Compound Name	Dexpirronium		Phase 1	[102]
Synonyms	Anticholinergic compound (COPD), Meda Click to Show/Hide
External Link	TTD: D0L3CQ
Compound Name	MEDI7814		Phase 1	[103]
External Link	TTD: D0H0ZV
Compound Name	AZD-2551		Phase 1	[104]
External Link	TTD: D0E4GE
Compound Name	BI-137882		Phase 1	[105]
External Link	TTD: D0B7TM
Compound Name	GSK2256294		Phase 1	[106]
Synonyms	GSK-2256294 Click to Show/Hide
External Link	CID: 59448236 TTD: D0A8KQ
Compound Name	PUR0200		Phase 1	[107]
External Link	TTD: D09ZRB
Compound Name	MEDI-2338		Phase 1	[108]
External Link	TTD: D05UCW
Compound Name	QAK-423		Phase 1	[109]
External Link	TTD: D02PYM
Compound Name	POL-6014		Investigative	[110]
Synonyms	Serine protease inhibitors (inhaled, PEM, asthma/COPD), Polyphor Click to Show/Hide
External Link	TTD: D01OGV
Compound Name	Quinazoline derivative 12		Patented	[111]
Synonyms	PMID26936077-Compound-23 Click to Show/Hide
External Link	CID: 60163336 TTD: D0EC3H
Compound Name	Quinazoline derivative 10		Patented	[111]
Synonyms	PMID26936077-Compound-21 Click to Show/Hide
External Link	CID: 6737869 TTD: D0CM5P
Compound Name	Quinazoline derivative 11		Patented	[111]
Synonyms	PMID26936077-Compound-22 Click to Show/Hide
External Link	CID: 60163203 TTD: D08ZEM
Compound Name	PMID27998201-Compound-5		Patented	[112]
External Link	CID: 46202117 TTD: D05OIU
Compound Name	Telenzepine		Discontinued in Preregistration	[113]
Synonyms	Telenzepine [INN]; Telenzepinum [Latin]; Telenzepino [Spanish]; 80880-90-6; UNII-0990EG3K10; 0990EG3K10; NCGC00015987-05; DSSTox_RID_80752; DSSTox_CID_25209; 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one; DSSTox_GSID_45209; 4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10H-thieno(3,4-b)(1,5)benzodiazepin-10-one; Telenzepine hydrochloride; Telenzepine dihydrochloide; C19H22N4O2S; Telenzepino; Telenzepinum; Telenzepine dihydrochloride hydrate; BY-802; [3H](+)telenzepine Click to Show/Hide
External Link	CID: 5387 TTD: D0FX4J
Compound Name	Levcromakalim		Discontinued in Preregistration	[114]
Synonyms	Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o Click to Show/Hide
External Link	CID: 93504 TTD: D08DKA
Compound Name	Sibenadet		Discontinued in Phase 3	[115]
Synonyms	UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one Click to Show/Hide
External Link	CID: 183812 TTD: D0C5PA
Compound Name	Cilomilast		Discontinued in Phase 3	[116]
Synonyms	Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid Click to Show/Hide
External Link	CID: 151170 TTD: D02EMR DrugBank: DB03849
Compound Name	Rispenzepine		Discontinued in Phase 2	[117]
Synonyms	Nuvenzepine; DF-545 Click to Show/Hide
External Link	CID: 129505 TTD: D0XE5L
Compound Name	CDP840		Discontinued in Phase 2	[118]
Synonyms	Cdp-840; Cdp 840; CHEMBL32442; 4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; (R)-4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine; Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-; 162542-90-7; AC1L2SW5; SCHEMBL84490; 4-[2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine; GTPL9330; UTUUPXBCDMQYRR-HSZRJFAPSA-N; ZINC599006; PDSP2_001272; BDBM50064858; PDSP1_001288 Click to Show/Hide
External Link	CID: 127928 TTD: D0UG4T
Compound Name	CE-1037		Discontinued in Phase 2	[119]
Synonyms	SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037) Click to Show/Hide
External Link	CID: 131801066 TTD: D0T5GT
Compound Name	MLN-977		Discontinued in Phase 2	[120]
Synonyms	CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy- Click to Show/Hide
External Link	CID: 9905233 TTD: D0P1TZ DrugBank: DB05431
Compound Name	GSK-159797		Discontinued in Phase 2	[33]
Synonyms	Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR Click to Show/Hide
External Link	CID: 11225217 TTD: D0N8MQ
Compound Name	Filaminast		Discontinued in Phase 2	[121]
Synonyms	Way-pda-641; UNII-CDD69JC61J; 141184-34-1; CDD69JC61J; (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONE O-(AMINOCARBONYL)OXIME; FIL; Filaminast [USAN:INN]; Filaminast (USAN/INN); SCHEMBL73844; SCHEMBL73843; CHEMBL590754; BDBM14771; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime; DB02660; D04185; 3'-(Cyclopentyloxy)-4'-methoxyacetophenone (E)-O-carbamoyloxime; [1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino] carbamate; (E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino Click to Show/Hide
External Link	CID: 9578243 TTD: D0H9KW DrugBank: DB02660
Compound Name	BRL-55834		Discontinued in Phase 2	[122]
Synonyms	Brl 55834; 131899-25-7; brl55834; SCHEMBL6369898; AC1L2Z70; DTXSID80157243; 3,4-Dihydro-2,2-dimethyl-4-(oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol; 2-Piperidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl)-, (3S-trans)- Click to Show/Hide
External Link	CID: 131442 TTD: D0GT4N
Compound Name	WC-3027		Discontinued in Phase 2	[123]
Synonyms	SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG Click to Show/Hide
External Link	TTD: D0G2CQ
Compound Name	AZD1236		Discontinued in Phase 2	[124]
Synonyms	(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl) Click to Show/Hide
External Link	CID: 24751752 TTD: D0E5YG DrugBank: DB11961
Compound Name	PF-610355		Discontinued in Phase 2	[125]
Synonyms	PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer Click to Show/Hide
External Link	CID: 11505444 TTD: D0AQ3H DrugBank: DB11871
Compound Name	AZD-5423		Discontinued in Phase 2	[126]
Synonyms	1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]- Click to Show/Hide
External Link	CID: 24825740 TTD: D09UFV DrugBank: DB12280
Compound Name	EPI-12323		Discontinued in Phase 2	[127]
External Link	TTD: D07EIJ
Compound Name	Tolafentrine		Discontinued in Phase 2	[128]
Synonyms	BY-4070 Click to Show/Hide
External Link	CID: 65990 TTD: D05YAS
Compound Name	Milveterol+Fluticasone		Discontinued in Phase 2	[129]
Synonyms	S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; 90566-53-3; S-(fluoromethyl) (6a,8x,11b,16a,17a)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate; AC1Q68ZV; AC1L1Y1V; AN-15808; s-(fluoromethyl)(6; A,8; I,11 Click to Show/Hide
External Link	CID: 62924 TTD: D04MOF
Compound Name	CS-003		Discontinued in Phase 2	[33]
External Link	CID: 9831640 TTD: D03ZKE
Compound Name	Darotropium		Discontinued in Phase 2	[130]
External Link	CID: 25195533 TTD: D03STA
Compound Name	KCO-912		Discontinued in Phase 2	[131]
External Link	TTD: D03NDI
Compound Name	AZD4818		Discontinued in Phase 2	[132]
Synonyms	18-HYDROXYASCOMYCIN; AC1L9IBR; SCHEMBL14434002 Click to Show/Hide
External Link	TTD: D00PFW
Compound Name	AZD5904		Discontinued in Phase 1	[133]
Synonyms	UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo- Click to Show/Hide
External Link	CID: 10264211 TTD: D0Y3LJ
Compound Name	AZD-6553		Discontinued in Phase 1	[134]
Synonyms	Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles Click to Show/Hide
External Link	TTD: D0X7WK
Compound Name	ZD-0892		Discontinued in Phase 1	[135]
Synonyms	CHEMBL55210; SCHEMBL7363455; CTK4D4091; BDBM50058391; HY-19254; 171964-73-1; CS-0014993; L-Prolinamide,N-(4-methoxybenzoyl)-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-; (S)-1-[(S)-2-(4-Methoxy-benzoylamino)-3-methyl-butyryl]-pyrrolidine-2-carboxylic acid Click to Show/Hide
External Link	CID: 9892148 TTD: D0WY9H
Compound Name	AZD-7140		Discontinued in Phase 1	[136]
External Link	TTD: D0TN3D
Compound Name	AZD-4407		Discontinued in Phase 1	[137]
Synonyms	ZD-4407 Click to Show/Hide
External Link	TTD: D0P3CF
Compound Name	QAN-747		Discontinued in Phase 1	[138]
External Link	TTD: D0L3VA
Compound Name	Revatropate		Discontinued in Phase 1	[33]
Synonyms	UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R(S(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate Click to Show/Hide
External Link	CID: 9690123 TTD: D09LMX
Compound Name	AZD-2315		Discontinued in Phase 1	[139]
Synonyms	ZD-2315 Click to Show/Hide
External Link	TTD: D08GKD
Compound Name	AZD-8309		Discontinued in Phase 1	[140]
External Link	TTD: D07TTI
Compound Name	AZD8075		Discontinued in Phase 1	[141]
External Link	TTD: D06XSG
Compound Name	AZD8566		Discontinued in Phase 1	[142]
External Link	TTD: D06EMW
Compound Name	AE-3763		Discontinued in Phase 1	[143]
External Link	CID: 9807572 TTD: D06DET
Compound Name	FR167653		Discontinued in Phase 1	[144]
Synonyms	HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818 Click to Show/Hide
External Link	CID: 135484078 TTD: D05QMG
Compound Name	SB-332235		Discontinued in Phase 1	[145]
Synonyms	1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea Click to Show/Hide
External Link	CID: 9887803 TTD: D03PDY
Compound Name	AZD5985		Discontinued in Phase 1	[146]
External Link	CID: 9811072 TTD: D01RVS
Compound Name	Rilmakalim		Discontinued in Phase 1	[147]
Synonyms	Hoe-234 Click to Show/Hide
External Link	CID: 65966 TTD: D01KHX
Compound Name	SCH-351591		Discontinued in Phase 1	[148]
Synonyms	SCH 351591; UNII-G6EF7V146S; CHEMBL250546; G6EF7V146S; CHEBI:77774; N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide; 444659-43-2; N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide; SCH351591; SCHEMBL157018; DTXSID8044125; NOCAS_44125; BDBM50219270; D 4396; 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide; 5-Quinolinecarboxamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- ( Click to Show/Hide
External Link	CID: 9802841 TTD: D01FXD
Compound Name	AZD-3342		Discontinued in Phase 1	[149]
External Link	TTD: D01CAJ
Compound Name	RS-504393		Preclinical	[150]
Synonyms	300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463 Click to Show/Hide
External Link	CID: 9953769 TTD: D0X4SI
Compound Name	AZD-7928		Preclinical	[151]
External Link	TTD: D0KJ0U
Compound Name	GW-3333		Preclinical	[33]
Synonyms	SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; Gw 3333; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol Click to Show/Hide
External Link	CID: 216470 TTD: D03ESO
Compound Name	AZD-0902		Terminated	[152]
External Link	TTD: D0F7LE
Compound Name	AR-C-89855		Terminated	[153]
Synonyms	AR-C68164AA; AR-C68475AA; AR-C69457AA; AR-C89855AA Click to Show/Hide
External Link	CID: 10206844 TTD: D0F6AB
Compound Name	ZARDAVERINE		Terminated	[154]
Synonyms	101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04 Click to Show/Hide
External Link	CID: 5723 TTD: D0F0CS DrugBank: DB02918
Compound Name	SSR-69071		Terminated	[155]
Synonyms	SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4 Click to Show/Hide
External Link	CID: 9872438 TTD: D0B3MV
Compound Name	AZD-2914		Terminated	[156]
External Link	TTD: D0A4VI
Compound Name	NIK-616		Terminated	[157]
External Link	TTD: D07UHY
Compound Name	AZD-0275		Terminated	[158]
External Link	TTD: D03DYB
Compound Name	AD-313		Terminated	[159]
External Link	TTD: D01KWB
Compound Name	ML-03		Terminated	[160]
Synonyms	Cystic fibrosis therapy, Milkhaus; HP-3; Respiratory therapeutics, Milkhaus Click to Show/Hide
External Link	TTD: D00GDN
Compound Name	PUP-1		Investigative	[161]
Synonyms	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen Click to Show/Hide
External Link	TTD: D0Y0BZ
Compound Name	OT-010		Investigative	[162]
Synonyms	OT-010 (inhaled dry powder, asthma/COPD); OT-010 (inhaled dry powder, asthma/COPD), Oriel Therapeutics; OT-010 (inhaled dry powder, asthma/COPD), Sandoz Click to Show/Hide
External Link	TTD: D0XM6L
Compound Name	TRN-101		Investigative	[163]
Synonyms	Dual ROCK1/ROCK2 inhibitor (inhalant, COPD), Theron Pharmaceuticals; Dual Rho kinase 1/ Rho kinase2 inhibitor (inhalant, COPD), Theron Pharmaceuticals Click to Show/Hide
External Link	TTD: D0X8UW
Compound Name	PD-3766		Investigative	[162]
Synonyms	RAC GTPase inhibitor (COPD), P2D Biosciences; Ras related C3 botulinum substrate guanosine triphosphatase inhibitor (COPD), P2D Biosciences Click to Show/Hide
External Link	TTD: D0X3QL
Compound Name	EP-102		Investigative	[164]
External Link	TTD: D0QM3Q
Compound Name	RBx-343E48F0		Investigative	[165]
External Link	TTD: D0OY7A
Compound Name	ZP-003		Investigative	[162]
External Link	TTD: D0M6XE
Compound Name	CHF-5480		Investigative	[166]
Synonyms	PDE 4 inhibitors (COPD/asthma); PDE 4 inhibitors (COPD/asthma), Chiesi Click to Show/Hide
External Link	TTD: D0K9PS
Compound Name	ADC-7828		Investigative	[110]
Synonyms	Neutrophil elastase inhibitors (inhaled, CF/COPD); Neutrophil elastase inhibitor (inhaled, cystic fibrosis/chronic obstructive pulmonary disease), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Pulmagen Click to Show/Hide
External Link	TTD: D0K2MT
Compound Name	SOM-0525		Investigative	[162]
External Link	TTD: D0I9RB
Compound Name	MBS-103		Investigative	[162]
Synonyms	Bismuth thiol based antibacterial agent (inhaled, pulmonary tuberculosis), Microbion; Bismuth thiol based agent (inhalant, pulmonary tuberculosis/cystic fibrosis/lung infection/COPD/pneumonia), Microbion Click to Show/Hide
External Link	TTD: D0I5IS
Compound Name	ADS-0101		Investigative	[167]
Synonyms	ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta Click to Show/Hide
External Link	TTD: D0G9XS
Compound Name	DX-2300		Investigative	[162]
Synonyms	Kallikrein-1 inhibitors (asthma); Kallikrein-1 inhibitors (asthma), Dyax Click to Show/Hide
External Link	TTD: D0F4FV
Compound Name	YPL-1101		Investigative	[162]
External Link	TTD: D0C9LE
Compound Name	J-104135		Investigative	[168]
Synonyms	UNII-6137X5QNJF; 6137X5QNJF; J-104871; SCHEMBL15207668; SCHEMBL15207665; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-pentenyl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-penten-1-yl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 191088-19-4; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-(((2-(1,3-benzodioxol-5-yl)-5-(2-benzoxa Click to Show/Hide
External Link	CID: 9962301 TTD: D0BP7C
Compound Name	SOM-1033		Investigative	[162]
External Link	TTD: D0AX0V
Compound Name	PF-613322		Investigative	[162]
Synonyms	Beta 2 adrenoceptor agonists (COPD); UK-503590; Beta 2 adrenoceptor agonists (COPD),Pfizer Click to Show/Hide
External Link	TTD: D08GZX
Compound Name	MDT-011		Investigative	[162]
External Link	TTD: D04OPS
Compound Name	ZP-013		Investigative	[162]
External Link	TTD: D04OBS
Compound Name	PYM-60001		Investigative	[162]
Synonyms	TRPV1-modulators Click to Show/Hide
External Link	TTD: D03QUJ
Compound Name	AMA-237		Investigative	[163]
Synonyms	AMA-63; ROCK inhibitors (COPD); ROCK inhibitors (COPD), Amakem Click to Show/Hide
External Link	TTD: D02RYE
Compound Name	CDP-146		Investigative	[162]
Synonyms	CT-8730; MAPK antagonists, Celltech; NG-1054; P38 MAP kinase inhibitor, Celltech; P38 kinase inhibitor, Celltech Click to Show/Hide
External Link	TTD: D01RSK
Compound Name	X-072-NAB		Investigative	[162]
Synonyms	NATHMAB (COPD), XBiotech Click to Show/Hide
External Link	TTD: D01HOT
Compound Name	MMP-408		Investigative	[161]
Synonyms	MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth Click to Show/Hide
External Link	TTD: D00NPE
Compound Name	UR-5908		Investigative	[162]
Synonyms	COPD therapy, UBE Industries Click to Show/Hide
External Link	TTD: D00JBM

References

Ref 1	Role of DNMT3a expression and nuclear translocation under ELAVL1 mediation for dendritic cell function and Th17/Treg balance in COPD. Transl Res. 2025 May;279:1-15. doi: 10.1016/j.trsl.2025.03.002. Epub 2025 Mar 12.
Ref 2	DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7449).
Ref 5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6962).
Ref 6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 367).
Ref 7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
Ref 8	Clinical pipeline report, company report or official report of Novartis.
Ref 9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 559).
Ref 10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
Ref 11	2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 12	Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76.
Ref 13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 413).
Ref 14	Improving oxygenation during bronchopulmonary lavage using nitric oxide inhalation and almitrine infusion. Anesth Analg. 1999 Aug;89(2):302-4.
Ref 15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7479).
Ref 16	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
Ref 17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7543).
Ref 18	FDA Approves Symbicort for Chronic Obstructive Pulmonary Disease
Ref 19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7455).
Ref 20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
Ref 21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5484).
Ref 22	Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
Ref 24	Duaklir Genuair approved in the European Union for chronic obstructive pulmonary disease
Ref 25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028430)
Ref 26	ClinicalTrials.gov (NCT00911651) Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
Ref 27	ClinicalTrials.gov (NCT04701983) Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 28	ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
Ref 29	ClinicalTrials.gov (NCT05878769) A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
Ref 30	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015 Aug 13:1-11.
Ref 31	ClinicalTrials.gov (NCT02343458) Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD. U.S. National Institutes of Health.
Ref 32	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
Ref 33	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
Ref 34	ClinicalTrials.gov (NCT00971035) A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
Ref 35	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029986)
Ref 36	Clinical pipeline report, company report or official report of Novartis.
Ref 37	ClinicalTrials.gov (NCT01316900) 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
Ref 38	ClinicalTrials.gov (NCT02554786) A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma.
Ref 39	ClinicalTrials.gov (NCT02276222) A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD. U.S. National Institutes of Health.
Ref 40	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7730).
Ref 41	ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 42	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
Ref 43	ClinicalTrials.gov (NCT04882124) A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 44	ClinicalTrials.gov (NCT03645434) A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD. U.S.National Institutes of Health.
Ref 45	ClinicalTrials.gov (NCT02272634) A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD. U.S.National Institutes of Health.
Ref 46	ClinicalTrials.gov (NCT03414541) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Chronic Obstructive Pulmonary Disease Patients. U.S.National Institutes of Health.
Ref 47	ClinicalTrials.gov (NCT04268823) A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 48	ClinicalTrials.gov (NCT04540042) A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 in Subjects With Chronic Obstructive Pulmonary Disease (Part 2). U.S.National Institutes of Health.
Ref 49	ClinicalTrials.gov (NCT03118765) A Dose Ranging, Parallel Group, Active (Spiriva? Respimat?) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
Ref 50	ClinicalTrials.gov (NCT02479412) A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma.
Ref 51	Clinical pipeline report, company report or official report of Amarillo Biosciences.
Ref 52	ClinicalTrials.gov (NCT00874497) Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema. U.S. National Institutes of Health.
Ref 53	ClinicalTrials.gov (NCT00483743) Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients. U.S. National Institutes of Health.
Ref 54	ClinicalTrials.gov (NCT00464932) Vasoactive Intestinal Peptide in COPD. U.S. National Institutes of Health.
Ref 55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7680).
Ref 56	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8499).
Ref 57	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8500).
Ref 58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495)
Ref 59	ClinicalTrials.gov (NCT01332097) Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation. U.S. National Institutes of Health.
Ref 60	ClinicalTrials.gov (NCT02109406) Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD. U.S. National Institutes of Health.
Ref 61	ClinicalTrials.gov (NCT01426009) Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101 in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study. U.S. National Institutes of Health.
Ref 62	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7818).
Ref 63	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026746)
Ref 64	ClinicalTrials.gov (NCT01033487) A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
Ref 65	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 841).
Ref 66	ClinicalTrials.gov (NCT01006161) Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1). U.S. National Institutes of Health.
Ref 67	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024247)
Ref 68	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 69	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7582).
Ref 70	A novel phosphodiesterase 4 inhibitor template. Expert Opinion on Therapeutic Patents,2003, 13(6), 929-933.
Ref 71	ClinicalTrials.gov (NCT01215279) AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) in AstraZeneca.
Ref 72	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8420).
Ref 73	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7826).
Ref 74	ClinicalTrials.gov (NCT00648245) Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD. U.S. National Institutes of Health.
Ref 75	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8179).
Ref 76	ClinicalTrials.gov (NCT00150397) A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics. U.S. National Institutes of Health.
Ref 77	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022098)
Ref 78	ClinicalTrials.gov (NCT01708057) A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
Ref 79	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016274)
Ref 80	ClinicalTrials.gov (NCT01972776) A Safety, Tolerability and Efficacy Study in COPD Patients With QBM076.. U.S. National Institutes of Health.
Ref 81	ClinicalTrials.gov (NCT00939211) The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
Ref 82	ClinicalTrials.gov (NCT01068613) Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
Ref 83	ClinicalTrials.gov (NCT02238483) A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy. U.S. National Institutes of Health.
Ref 84	ClinicalTrials.gov (NCT01154101) Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis. U.S. National Institutes of Health.
Ref 85	Clinical pipeline report, company report or official report of Theravance.
Ref 86	ClinicalTrials.gov (NCT02382510) Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics. U.S. National Institutes of Health.
Ref 87	ClinicalTrials.gov (NCT00703391) A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
Ref 88	ClinicalTrials.gov (NCT02324972) Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis. U.S. National Institutes of Health.
Ref 89	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6563).
Ref 90	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8497).
Ref 91	ClinicalTrials.gov (NCT01461915) Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane. U.S. National Institutes ofHealth.
Ref 92	ClinicalTrials.gov (NCT05643729) A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of ZofinTM for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 93	ClinicalTrials.gov (NCT03235726) A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Inhalation Powder in Healthy Participants and Participants With Moderate Chronic Obstructive Pulmonary Disease (COPD) Including Evaluation of Environmental and Healthy By-stander Exposure Levels During Dosing. U.S.National Institutes of Health.
Ref 94	ClinicalTrials.gov (NCT04759807) A Phase 1b 3-way Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Once Daily Doses of PUR1800 in Adult Patients With Stable Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
Ref 95	ClinicalTrials.gov (NCT04656275) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Oral Doses of BI 1323495 Bid Versus Placebo in Patients With Non-cystic Fibrosis Bronchiectasis (Randomised, Double-blind, Placebo-controlled, Parallel Group Trial). U.S.National Institutes of Health.
Ref 96	ClinicalTrials.gov (NCT05677347) A Randomized, Double-blind, Placebo Controlled, Single and Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
Ref 97	ClinicalTrials.gov (NCT01166698) Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects. U.S. National Institutes of Health.
Ref 98	ClinicalTrials.gov (NCT01009424) A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
Ref 99	ClinicalTrials.gov (NCT01889160) Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels. U.S. National Institutes of Health.
Ref 100	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013990)
Ref 101	ClinicalTrials.gov (NCT00984477) Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects. U.S. National Institutes of Health.
Ref 102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028438)
Ref 103	ClinicalTrials.gov (NCT01544361) A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers. U.S. National Institutes of Health.
Ref 104	ClinicalTrials.gov (NCT00860353) Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551. U.S. National Institutes of Health.
Ref 105	ClinicalTrials.gov (NCT01348165) Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers. U.S. National Institutes of Health.
Ref 106	Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301.
Ref 107	ClinicalTrials.gov (NCT01921712) A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients. U.S. National Institutes of Health.
Ref 108	ClinicalTrials.gov (NCT01322594) A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
Ref 109	ClinicalTrials.gov (NCT01197287) Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
Ref 110	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
Ref 111	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 112	Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.
Ref 113	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000603)
Ref 114	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000036)
Ref 115	Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17.
Ref 116	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7407).
Ref 117	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003718)
Ref 118	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003087)
Ref 119	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003784)
Ref 120	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007577)
Ref 121	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003918)
Ref 122	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001581)
Ref 123	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021444)
Ref 124	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7844).
Ref 125	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025582)
Ref 126	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031497)
Ref 127	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015988)
Ref 128	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003767)
Ref 129	Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 130	Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev. 2009 Nov;29(6):867-902.
Ref 131	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017535)
Ref 132	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025769)
Ref 133	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7728).
Ref 134	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703)
Ref 135	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009537)
Ref 136	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017126)
Ref 137	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009803)
Ref 138	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023203)
Ref 139	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009741)
Ref 140	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017125)
Ref 141	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029210)
Ref 142	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027710)
Ref 143	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015539)
Ref 144	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012873)
Ref 145	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014165)
Ref 146	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029299)
Ref 147	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001252)
Ref 148	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010874)
Ref 149	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019126)
Ref 150	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 781).
Ref 151	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024139)
Ref 152	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)
Ref 153	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263)
Ref 154	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000057)
Ref 155	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014569)
Ref 156	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022142)
Ref 157	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020194)
Ref 158	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019127)
Ref 159	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015052)
Ref 160	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008813)
Ref 161	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
Ref 162	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 163	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
Ref 164	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031503)
Ref 165	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17).
Ref 166	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
Ref 167	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
Ref 168	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map